Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023

Rhea-AI Summary

Agios Pharmaceuticals (Nasdaq: AGIO) has announced its presentation schedule at the RBC Capital Markets Global Healthcare Conference on May 16, 2024, at 9 a.m. ET. This conference is a key opportunity for investors and analysts to engage with the company.

Participants can access a live webcast via the Investors section of the Agios website, with an archived replay available for two weeks post-presentation. Agios is recognized for its innovative work in cellular metabolism and offers therapies for rare diseases, including a first-in-class pyruvate kinase activator for PK deficiency.

The company’s pipeline includes investigational therapies for conditions such as sickle cell disease and thalassemia, reinforcing its commitment to developing solutions for serious health challenges.

CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2024, at 9 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU) and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.

Contacts:

Investor Contact
Cecilia Jones, Chief Financial Officer
Agios Pharmaceuticals
IR@agios.com

Media Contact
Dan Budwick
1AB Media
dan@1abmedia.com  

FAQ

What date is Agios Pharmaceuticals presenting at the RBC Capital Markets Global Healthcare Conference?

Agios Pharmaceuticals will present on May 16, 2024.

What time is Agios Pharmaceuticals' presentation scheduled for?

The presentation is scheduled for 9 a.m. ET.

Where can I access the Agios Pharmaceuticals conference presentation?

The presentation can be accessed as a live webcast on the Investors section of the Agios website.

How long will the webcast of Agios Pharmaceuticals' presentation be available?

A replay of the webcast will be available for at least two weeks after the presentation.

What is Agios Pharmaceuticals known for?

Agios Pharmaceuticals is known for pioneering therapies for rare diseases and its leadership in cellular metabolism.